Altamira Therapeutics Stock Today

CYTO Stock  USD 0.40  0.02  4.17%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 37

 
High
 
Low
Below Average
Altamira Therapeutics is selling at 0.4025 as of the 28th of November 2024; that is 4.17 percent decrease since the beginning of the trading day. The stock's open price was 0.42. Altamira Therapeutics has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Altamira Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
6th of August 2014
Category
Healthcare
Classification
Health Care
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda. Altamira Therapeutics is traded on NASDAQ Exchange in the United States. The company has 3.78 M outstanding shares of which 31.09 K shares are currently shorted by private and institutional investors with about 1.08 trading days to cover. More on Altamira Therapeutics

Moving together with Altamira Stock

  0.92FDMT 4D Molecular TherapeuticsPairCorr
  0.8JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.89MRK Merck Company Fiscal Year End 6th of February 2025 PairCorr
  0.65INKT Mink TherapeuticsPairCorr

Moving against Altamira Stock

  0.88BMY Bristol Myers Squibb Aggressive PushPairCorr
  0.74NAMS NewAmsterdam PharmaPairCorr
  0.58PHVS Pharvaris BVPairCorr
  0.5PMVP Pmv PharmaceuticalsPairCorr
  0.45ESLAW Estrella ImmunopharmaPairCorr
  0.43OPT OptheaPairCorr

Altamira Stock Highlights

President, FounderThomas Meyer
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities844.5 K888.9 K
Notably Down
Very volatile
Non Current Liabilities Total329.3 K346.6 K
Notably Down
Very volatile
Total Assets7.3 M7.7 M
Notably Down
Pretty Stable
Total Current Assets1.2 M1.2 M
Notably Down
Pretty Stable
Debt Levels
Altamira Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Altamira Therapeutics' financial leverage. It provides some insight into what part of Altamira Therapeutics' total assets is financed by creditors.
Liquidity
Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity.

Depreciation

79,935.54
Altamira Therapeutics (CYTO) is traded on NASDAQ Exchange in USA. It is located in Clarendon House, Hamilton, Bermuda, HM 11 and employs 10 people. Altamira Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.59 M. Altamira Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 3.78 M outstanding shares of which 31.09 K shares are currently shorted by private and institutional investors with about 1.08 trading days to cover. Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Altamira Therapeutics Probability Of Bankruptcy
Ownership Allocation
Almost 96.35 percent of Altamira Therapeutics outstanding shares are held by general public with 0.52 (percent) owned by insiders and only 3.13 % by other corporate entities.
Check Altamira Ownership Details

Altamira Stock Institutional Holders

InstituionRecorded OnShares
Armistice Capital, Llc2024-09-30
101.4 K
Citadel Advisors Llc2024-09-30
14.8 K
Morgan Stanley - Brokerage Accounts2024-06-30
1.9 K
Ubs Group Ag2024-06-30
1.7 K
Group One Trading, Lp2024-06-30
14.0
Lri Investments, Llc2024-06-30
1.0
Tower Research Capital Llc2024-06-30
0.0
View Altamira Therapeutics Diagnostics

Altamira Therapeutics Historical Income Statement

At this time, Altamira Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 28th of November 2024, Selling General Administrative is likely to grow to about 4 M, while Interest Expense is likely to drop about 544.9 K. View More Fundamentals

Altamira Stock Against Markets

Altamira Therapeutics Corporate Management

When determining whether Altamira Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Altamira Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Altamira Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Altamira Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.82
Revenue Per Share
0.917
Quarterly Revenue Growth
(0.64)
Return On Assets
(0.57)
Return On Equity
(3.69)
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.